评估EBUS-TBNA细胞学样本中肺癌生物标志物谱以决定靶向治疗
Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
作者信息
Gürün Kaya Aslıhan, Çiledağ Aydın, Erol Serhat, Öz Miraç, Doğan Mülazımoğlu Deniz, Işık Özlem, Özakıncı Hilal, Çiftçi Fatma, Şen Elif, Ceyhan Koray, Kaya Akın, Karnak Demet, Çelik Gökhan, İsmail Savaş
机构信息
Department of Chest Diseases, 63990Ankara University Faculty of Medicine, Ankara, Turkey.
Department of Pathology, 63990Ankara University Faculty of Medicine, Ankara, Turkey.
出版信息
Scott Med J. 2022 Feb;67(1):18-27. doi: 10.1177/00369330221078995. Epub 2022 Feb 11.
BACKGROUND
Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.
AIM
The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.
METHODS
We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.
RESULTS
A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.
CONCLUSION
EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.
背景
指南建议对非小细胞肺癌（NSCLC）患者进行表皮生长因子受体（EGFR）、间变性淋巴瘤激酶（ALK）、BRAF和ROS原癌基因1（ROS1）基因检测以及程序性死亡配体1（PD-L1）蛋白表达检测。研究报告称，支气管内超声引导下经支气管针吸活检术（EBUS-TBNA）可为癌症生物标志物分析提供足够的材料，但对此仍存在担忧。
目的
本研究的目的是评估EBUS-TBNA用于检测肺癌生物标志物的充足性。
方法
我们回顾性分析了2011年12月至2020年12月期间接受EBUS-TBNA检查并分析EGFR、ALK、ROS-1、BRAF和PD-L1表达的NSCLC患者。
结果
共有394例患者纳入本研究。EGFR突变和ALK融合是最常检测的生物标志物。EBUS-TBNA用于生物标志物检测的充足率在EGFR检测中为99.0%，ALK检测中为99.1%，ROS1检测中为97.2%，BRAF检测中为100%，PD-L1检测中为99.3%。多变量分析显示，组织学类型、NSCL治疗史、取样病变的大小或18氟脱氧葡萄糖摄取情况与TBNA用于生物标志物检测的充足性均无关联。
结论
EBUS-TBNA可为EGFR、ALK、ROS-1、BRAF和PD-L1表达的生物标志物检测提供充足的材料。
Zotero 插件